
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, DC 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **April 14, 2015**

AngioDynamics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

000-50761
(Commission File Number)

11-3146460
(IRS Employer Identification No.)

14 Plaza Drive Latham, New York
(Address of Principal Executive Offices)

12110
(Zip Code)

Registrant's telephone number, including area code: **(518) 795-1400**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01 – Regulation FD Disclosure.

On April 14, 2015, Joseph M. DeVivo, President and Chief Executive Officer of AngioDynamics, Inc. (the “Company”), and Mark Frost, Executive Vice President and Chief Financial Officer of the Company, will make a presentation to certain investors at the Needham & Company 14th Annual Healthcare Conference. The conference slides are furnished herewith as Exhibit 99.1.

The slides are being furnished pursuant to Item 7.01 and the information contained therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information in Exhibit 99.1 shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits.

99.1 Presentation slides for the Needham & Company 14th Annual Healthcare Conference held on April 14, 2015.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 14, 2015

ANGIODYNAMICS, INC.

/s/ Stephen A. Trowbridge
Stephen A. Trowbridge

Senior Vice President and General Counsel

EXHIBIT INDEX

Exhibit No.	Description	Paper (P) or Electronic (E)
99.1	Presentation slides for the Needham & Company 14th Annual Healthcare Conference held on April 14, 2015.	E

Needham & Company

14th Annual Healthcare Conference

Joseph M. DeVivo, President & CEO

Mark Frost, Executive Vice President & CFO

April 14, 2015



Forward-Looking Statements

Notice Regarding Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2014; its Annual Report on Form 10-K/A for the fiscal year ended May 31, 2014; its quarterly reports on Form 10-Q for the fiscal quarters ended August 31, 2014, and November 30, 2014; and the current report on Form 8-K, filed with the SEC on March 2, 2015. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, NanoKnife has been cleared by the FDA for use in the surgical ablation of soft tissue. NanoKnife has not been cleared for the treatment or therapy of a specific disease or condition. This document may discuss the use of NanoKnife for specific clinical indications for which it is not cleared in the United States at this time.

EmboMedics microsphere products have not been reviewed by the U.S. Food and Drug Administration or any other international regulatory body at this time; as such they are currently not available for sale by AngioDynamics.

Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported non-GAAP sales growth, non-GAAP gross margin, non-GAAP operating income, adjusted EBITDA (income before interest, taxes, depreciation and amortization), non-GAAP net income and non-GAAP earnings per share. Additionally, this press release evaluates results on a constant currency basis. As a non-GAAP measure, constant currency excludes the impact of foreign currency exchange rate fluctuations. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.



Performance Update

Q3 FY15 Results

	Q3 FY15 Actual	Q3 FY15 ^b
Sales	\$86.6M	\$87.6M
Adjusted EPS ^(a)	\$0.12	\$0.14

Recent Events

- EmboMedics Agreement
- Next generation AngioVac launch
- Celerity "no chest x-ray" claim received
- Morpheus recall and discontinuance
- HealthTrust PICC contract
- Chris Crisman named SVP, Global PV Franchise
- NanoKnife German OPS procedure codes received
- ANGO Added to S&P SmallCap 600 Index
- Celerity U.S. launch
- BioFlo DuraMax chronic hemodialysis catheter CE Mark
- Launch of Novation new technology contract for BioFlo PICCs & Ports
- Five NanoKnife clinical papers
- AVA meeting includes BioFlo PICC data, first Celerity data
- FDA warning letter regarding Glens Falls and Marlborough facilities

a) Adjusted results exclude costs relating to acquisitions, debt financing, business restructuring, litigation, facility consolidations, amortization of book step-up of acquired inventory, revaluation of contingent earn outs related to acquisitions, recalls, product discontinuations and amortization of intangible assets.

b) On a constant currency basis.



Profile of AngioDynamics

Global, leading provider of innovative, image guided, minimally invasive solutions.

- Three Franchises – Peripheral Vascular, Vascular Access and Oncology/Surgery
- Founded 1988 | IPO May 2004—ANGO (NASDAQ)
- Worldwide presence with 1,300 employees and 7 operating locations, as well as a 210+ global sales team in U.S., Australia, Canada, France, Germany, Netherlands and UK



- Present in 50+ markets through 110+ distributors



Innovative Technology

Develop innovative technology that improves patient outcomes while reducing overall healthcare costs



Above Market Growth

Focusing investments in categories and geographic markets that offer sustainable, profitable growth



Operational Excellence

Enhancing profitability by driving operation excellence across the entire organization



Leadership



Mark Frost
EVP & CFO



Joseph M. DeVivo
President & CEO



John Soto
EVP & CCO



Mark Stephens
SVP, Administration



Stephen Trowbridge
SVP & General Counsel



Benjamin Davis
SVP, Business Development



Barbara Kucharczyk
VP, Operations



Gary Barrett
VP, RA/QA



Our Strategy is Working

Growth Driver Performance*



38%
YTD FY15 over YTD FY14
AngioVac GROWTH



76%
YTD FY15 over YTD FY14
BioFlo GROWTH



30%
YTD FY15 over YTD FY14
Microwave
Ablation GROWTH



18%
YTD FY15 over YTD FY14
NanoKnife GROWTH

* As of the close of the third quarter on Feb. 28, 2015.


AngioDynamics in FY14

FY14
4% Sales Growth; 51% GM

Sales by Franchise

- Peripheral Vascular: \$193M
- Vascular Access: \$106M
- Oncology/Surgery: \$49M

Total: \$348M*



*Excludes BSC supply agreement. With supply agreement FY14 net sales were \$354.5M




AngioDynamics in FY20

FY20
10% 5YR Sales CAGR; 60% GM

Sales by Franchise

- Peripheral Vascular: ~\$300M
- Vascular Access: ~\$200M
- Oncology/Surgery: ~\$100M

Total: ~\$600M



Operational Excellence




\$15-18M
TO BE
SAVED
OVER FOUR YEARS

- Enterprise resource planning implementation
- Consolidation of N.Y. distribution center
- Consolidation of N.Y. manufacturing plants
- Supply chain optimization
- Product rationalization
- Lean initiatives




Strong Product Development Pipeline*



*Timelines are estimated and subject to change.



Clinical Studies*



Investigator Initiated Trials

O/S

- LEIDEN – NanoKnife Pancreas
- CROES Registry
- NEAT – NanoKnife Prostate
- CROES II – NanoKnife Prostate
- AHPBA Registry

PV

- EVLT Registry
- AngioVac Registry

VA

- BioFlo Dialysis
- BioFlo PICCs
- BioFlo Ports


*Timelines are estimated and subject to change.



Peripheral Vascular Franchise



<i>\$ in millions</i>	FY14	YoY Growth	YTD FY15*
Fluid Mgmt.	\$79	-3%	2%
Venous	\$55	18%	-3%
Thrombus Mgmt.	\$14	109%	16%
Other Core Products	\$45	5%	-2%
Total PV	\$193	7%	1%




* As of the close of the third quarter on Feb. 28, 2015.




Large Unmet Opportunity

Venous Thromboembolism (VTE) Incidence

- ~1 Million VTE Events per Year in US
- ~300,000 VTE Deaths per Year in US - #3 cause



Additional: Annual Incidence



Current Options

Oral
Anticoagulation

Systemic and
Catheter Directed
Thrombolysis

Mechanical /
PharmacoMechanical

Surgical
Embolectomy

Heik JA, et al. Blood. 2005;106:267A.
Murphy SL, et al. Deaths: Preliminary Data for 2010. National Vital Statistics Reports; 2012

Solution: AngioVac



Everyone remembers their first time.

Pioneering options in venous drainage.



AngioVac
venous catheter




Find out how the design of the AngioVac catheter facilitates an easy removal of soft, fresh thrombi or emboli.

www.angiovac.com

www.angiodynamics.com

angiodynamics

*AngioVac is a registered trademark of AngioDynamics, Inc. All other trademarks are the property of their respective owners. © 2014 AngioDynamics, Inc. All rights reserved. AngioVac is a registered trademark of AngioDynamics, Inc. All other trademarks are the property of their respective owners. © 2014 AngioDynamics, Inc. All rights reserved.



angiodynamics

Solution: AngioVac



Everyone remembers their first time.

Pioneering options in venous drainage.



AngioVac




Find out how the design of the AngioVac cannula facilitates an easy removal of soft, fresh thrombi or emboli.

www.angiodynamics.com

www.angiodynamics.com

angiodynamics


* Intellectual property and other relevant information may be contained herein. All rights reserved. © 2014 AngioDynamics, Inc. All other trademarks are the property of their respective owners. AngioDynamics, Inc. is an Equal Opportunity Employer. M/F/V. AngioDynamics, Inc. is an Equal Opportunity Employer. M/F/V. AngioDynamics, Inc. is an Equal Opportunity Employer. M/F/V.



angiodynamics

Solution: Laser Vein Treatment

Large Market Opportunity



Projected Growth



Vascular Access Franchise



<i>\$ in millions</i>	FY14	YoY Growth	YTD FY15*
PICCs	\$51	0%	-2%
Ports	\$32	3%	9%
Dialysis	\$19	-2%	5%
Total VA	\$106	0%	3%



* As of the close of the third quarter on Feb. 28, 2015.

BioFlo Technology

The BioFlo family of products, including PICCs, ports and dialysis catheters, are the only vascular access products manufactured with Endexo Technology, a permanent and non-eluting integral polymer.



BioFlo Duraflo
at 100x magnification
Catheter has minimal visible
thrombus, fibrin sheath, or clot.



Conventional Non-Coated Catheter
at 10x Magnification
Catheter with thrombus accumulation



Heparin Coated Catheter
at 10x Magnification
Catheter with thrombus accumulation

Less Thrombus Accumulation

	BioFlo PICCs	BioFlo Ports	BioFlo Dialysis
<i>Vs. common PICC</i>	87% ¹	—	—
<i>Vs. non-coated conventional port catheters</i>	—	96% ²	—
<i>Vs. non-coated conventional dialysis catheters</i>	—	—	90% ³
<i>Vs. heparin-coated dialysis catheters</i>	—	—	83% ⁴

1. Based on benchtop test results which may not be indicative of clinical results. Data on file. 2. Based on benchtop testing performed up to two hours using bovine blood, which may not be indicative of clinical results. Data on file. 3. The reduction in thrombus accumulation (based on platelet count) is supported by acute in-vitro testing. Pre-clinical in-vitro evaluations do not necessarily predict clinical performance with respect to thrombus formation. 4. Based on benchtop testing performed up to two hours using bovine blood which may not be indicative of clinical results. Data on file.



Reducing Healthcare Costs

Clinical Results*

Facility 1

- 1,251 BioFlo PICCs placed
- 85% reduction in symptomatic UEDVT
- 7 UEDVTs reported from 1251 PICCs
- UEDVT rate of .45% versus prior 3.1%

Facility 2

- 272 BioFlo PICCs placed
- 42% reduction in Occlusions
- 19.7% reduction in baseline occlusion rate

Facility 3


- 776 BioFlo PICCs placed
- 65% reduction in tPA use
- 47% reduction in occlusions

Facility 4

- 1,212 BioFlo PICCs placed
- 65% reduction in declots
- 36% reduction in DVTs

Facility 5

- 533 BioFlo PICCs placed
- 66% reduction on occlusions
- 75% reduction in tPA
- 25% reduction in DVTs



*Clinical results were publicly reported by independent facilities based upon their individual clinical experience. These results do not reflect data gathered by AngioDynamics pursuant to a clinical trial. Individual results may vary from those set forth above.

Celerity Tip Location

Tip location, coupled with our innovative BioFlo Technology, will improve our competitive position in the PICC market.

Ease of use

- Use with existing ultrasound

Clinical efficacy

- Three lead EKG-based platform
- Predictable and reliable confirmation

Cost effective

- 50% less cost vs. competitors




- Fall 2013 – Canadian Launch
- March 6, 2014 – Acquired regulatory control over Celerity platform and rights to next generation technology
- Mid-summer 2014 – U.S. Clearance
- Fall 2014 – File for no x-ray
- Winter 2014/15 – No x-ray clearance
- Summer 2015 - Navigation



PICC Strategy

BioFlo PICC vs. Morpheus PICC Sales



Decision

- Company withdrew Morpheus PICC line from the market following unacceptable complaint levels

Financial Impact

- Q3 FY15 PICC revenues down 11%
- \$5 million inventory write-off
- Expected revenue reduction of \$1 million to \$1.5 million in Q4 FY15

Result


- Streamlined, robust PICC offering
- Sales force converting customers to other lines



Oncology/Surgery Franchise



<i>\$ in millions</i>	FY14	YoY Growth	YTD FY15*
Thermal Ablation	\$30	10%	5%
NanoKnife	\$14	6%	18%
Resection/Other	\$5	-18%	7%
Total O/S	\$49	5%	9%




* As of the close of the third quarter on Feb. 28, 2015.




Expanding Leadership in Tissue Ablation

AngioDynamics offers a full complement of tissue ablation products that provide clinicians maximum choice in treating patients.



Re-Entering the Embolization Market

On April 9, 2015, AngioDynamics entered an agreement with EmboMedics Inc., which develops injectable & resorbable microspheres and expects to file for U.S. FDA 510(k) clearance for the embolization of hypervascular tumors by January 2016.



\$150M

Worldwide
Addressable Market

Terms

- Initial \$2M equity investment
- May make \$9M additional investments based on milestones


Investment Strategy

- ✓ Novel Technology
- ✓ Highly margin accretive
- ✓ Worldwide rights for direct and distributor sales
- ✓ Pathway to own technology



International Growth Strategy

International Quarterly Growth Rates



Market Led, Efficient & Aligned

- Region-based business model improves competitiveness
- Increased direct market expansion
- New product introductions and full registration of product portfolio
- Delivering operating margin improvement
- Align talent and organization to ensure consistent execution of Company's strategy



a) On a constant currency basis.
b) As of the close of the third quarter on Feb. 28, 2015.



Fiscal Third Quarter Results

Sales

\$ in millions, except per share amounts

	Q3 2015 ^(a)	YOY Growth	YTD FY15 Growth ^(e)
WW	\$86.6	-2%	2%
WW ^{(c)(d)}	\$86.5	0%	3%
PV	\$46.2	-2%	1%
VA	\$26.4	-3%	3%
O/S	\$13.1	9%	9%
U.S. ^(c)	\$68.4	-2%	1%
Int'l	\$17.3	3%	10%
Int'l ^(d)	\$18.3	8%	13%
	Q3 2015 ^(b)	YOY Growth	YTD FY15 Growth ^(e)
Adjusted EBITDA	\$13.5	-3%	11%
Adjusted EPS	\$0.12	-13%	16%
Adjusted EPS ^(d)	\$0.14	0%	19%

Fiscal Guidance

\$ in millions, except per share amounts

	Q3	Full-Year
Sales ^(d)	\$90-\$94	\$356-\$360
Adjusted EPS ^(d)	\$0.13-\$0.16	\$0.57-\$0.60

(a) There is no difference in the number of sales days between the first quarter of fiscal 2014 and the first quarter of fiscal 2015.
 (b) Adjusted results include costs relating to acquisitions, debt financing, business restructurings, litigation, facility consolidations, direct costs of the Quality Call to Action program, amortization of intangible assets, and other non-recurring items.
 (c) Includes impact of our supply agreement.
 (d) Constant currency.
 (e) As of the close of the third quarter on Feb. 18, 2015.



Balance Sheet & Cash Flow

<i>\$ in millions</i>	Feb 28, 2015	May 31, 2014
Cash & investments	\$21.4	\$17.9
Net working capital	\$97.6	\$85.0
Total assets	\$783.1	\$798.9
Total debt	\$148.9	\$142.7
Total stockholder's equity	\$543.8	\$536.8

<i>\$ in millions, except per share amounts</i>	9 months ended Feb 28, 2015	9 Months ended Feb 28, 2014
Cash flow from operations	\$15.4	\$15.2
CFFO/share	\$0.43	\$0.43
Free cash flow	\$4.4	\$6.2



Adjusted Income Statement^(a)

<i>\$ in millions, except per share amounts</i>	9 months ended Feb 28, 2015	9 Months ended Feb 28, 2014
Sales	\$266.1	\$260.4
Gross margins	51.2%	50.8%
Operating expenses	\$105.4	\$105
Operating income	\$31.0	\$27.3
Operating margin	11.6%	10.5%
Net income	\$16.2	\$13.8
EPS	\$0.45	\$0.39
EBITDA	\$43.8	\$39.5

^{a)} Adjusted results exclude costs relating to acquisitions, debt financing, business restructuring, litigation, facility consolidations, amortization of bank step-up of acquired inventory, revaluation of contingent earn outs related to acquisitions, recalls, product discontinuations and amortization of intangible assets.



AngioDynamics Transformation

Investor Profile

- Major acquisitions – Navilyst (2012), Vortex Medical (2012), Microsulis (2013)
- Disruptive technology in PV, VA & O/S markets with strong product pipeline
- Significant International opportunity
- Operational Excellence Program in place to drive margin expansion
- Emerging GPO presence

FY20
Net Sales
\$600M
60%
Gross
Margin

Net Sales

	FY11	FY12	FY13	FY14	FY15 ^{a)}
Net Sales	\$216M	\$222M	\$342M	\$354M	\$358M
Reported Growth	0%	3%	54%	4%	1%
Pro Forma	0%	3%	-1% ^{b)}	4%	1%
Exc. BSC	-	-	-	5%	3% ^{c)}

a) FY15 revenue guidance midpoint.

b) On a pro forma basis prior year sales for AngioDynamics and Navilyst Medical were \$344.6 million.

c) On a constant currency basis.



Needham & Company

14th Annual Healthcare Conference

Joseph M. DeVivo, President & CEO

Mark Frost, Executive Vice President & CFO

April 14, 2015



